Guardant Health Inc. Stock News

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market c

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylatio

Starting in 2014, and even more notably in 2016 as Warren Buffett himself chipped in, Apple (NASDAQ: AAPL) became the benchmark company, and investors around the world were trying to find the ‘next

It's been nearly one and a half years since ChatGPT went live, but it sure doesn't feel like it. ChatGPT has shaken up many sectors, and triggered an AI revolution.

GH can prove to the market they have a competitive product in Shield that can gain a foothold in the roughly 50m unscreened CRC patient population. Shield's strongest adherence rate, with the potentia

While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by majo

Guardant Health, Inc. (GH) Q4 2023 Earnings Call Transcript

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street

Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago.

The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Citi 2

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estim

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023